Navigation Links
Dynavax to Present at CIBC World Markets and Acumen BioFin Rodman and Renshaw Healthcare Conferences
Date:11/1/2007

BERKELEY, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Michael S. Ostrach, Vice President and Chief Business Officer, will present an overview of the company at two investor conferences in New York City the first week of November. Ostrach will present at the CIBC World Markets 18th Annual Healthcare Conference on Monday, November 5, 2007 at 8:35 a.m. ET (5:35 a.m. PT). In addition, Ostrach will present at the Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference on Tuesday, November 6, 2007 at 4:45 p.m. ET (1:45 p.m. PT). Both presentations will be webcast.

To access the live audio broadcast and the subsequent archived audio recordings of the company presentation, please log onto the company's website at http://www.dynavax.com under the "Investors'" section.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV(TM), a hepatitis B vaccine in Phase 3 partnered with Merck & Co. Inc.; TOLAMBA(TM), a ragweed allergy immunotherapy in Phase 2; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The National Institutes of Health (NIH) partially funds our preclinical work on a vaccine for influenza. Symphony Dynamo, Inc. (SDI) funds our colorectal cancer trials and our preclinical hepatitis C therapeutic program, and Deerfield Management has committed funding for our allergy programs. While Deerfield, NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com.


'/>"/>
SOURCE Dynavax Technologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical ... recently joined their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, ... excited to add this excellent dermatology practice to our group’s medical services,” explains ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion ... deck space. Since the lift is mounted on wheels, it can be wheeled out of ... down kit, to fasten to the deck. "We have transformed the feedback from customers into ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... supplement development, announced it attended the January ECRM trade show to continue the marketing ... technologically advanced vitamin C supplement, known for providing 400 percent better absorption than traditional ...
(Date:1/20/2017)... ... ... International Protein, a company based out of Australia that focuses on developing ... trade show in Hilton Head, SC. , International Protein was founded by Christine ... of products that would elevate her fitness regime. At this ECRM trade show, Envall ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... 20, 2017 ResMed (NYSE: RMD ), BMC ... Winter Haven, Florida ) today announced they have agreed on ... 3B will be permitted to sell their existing products in exchange ... settlement payment to 3B to close the Florida ... an admission of liability or wrongdoing by any party. ...
(Date:1/21/2017)... 20, 2017  Today, during a plenary ... Pathways in Immunology, Growth Disorders and Cancer," ... INFI ) presented preclinical data for ... selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). Preclinical data showed ... resistance to checkpoint inhibition by remodeling the ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver Panel, Renal ... report to their offering. ... The global clinical laboratory testing market is expected ... innovative solutions on the grounds of maximum efficiency and minimum error ...
Breaking Medicine Technology: